Category: Interpretational.com

BOTHELL, Wash. & TOKYO–(BUSINESS WIRE[1])–Seattle Genetics, Inc[2]. (Nasdaq:SGEN) and Astellas Pharma Inc.[3] (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that a phase 3 trial of PADCEV® (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy. The results were reviewed by an independent Data Monitoring Committee following a planned interim analysis. The global EV-301...

SAN DIEGO–(BUSINESS WIRE[1])–Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) presented positive results today from a Phase 1 clinical trial of its Captisol-enabled (CE) Iohexol program at ASN Kidney Week 2019 in Washington, D.C. The CE-Iohexol program was established in January 2018 to develop a Captisol-enabled, next-generation contrast agent for diagnostic imaging with a reduced risk of renal toxicity. The trial achieved the...

Petroc Sumner, professor12, Solveiga Vivian-Griffiths, research assistant12, Jacky Boivin, professor2, Andy Williams, lecturer3, Christos A Venetis, senior lecturer4, Aimée Davies, research assistant2, Jack Ogden, research assistant2, Leanne Whelan, research assistant2, Bethan Hughes, research assistant2, Bethan Dalton, research assistant2, Fred Boy, senior lecturer5, Christopher D Chambers, professor12 1Cardiff University Brain Research Imaging Centre, School of Psychology, Cardiff University, Cardiff CF10 3AT,...

Maps are essential for any strategy. For autonomous cars, maps are the strategy. Away from the headlines, a global war is waged for interpretational jurisdiction in the mapping business:  Those who define the standards will reap the rewards.  At first glance, a relatively unknown Japanese company bought a little-known American outfit today.  Once you look at the bigtime backers of...